MET and lung cancer: Additionally, testing our FGFR1 resistance model against DNA- and RNA-directed lung cancer sequencing panels, as well as western blot analyses, allowed us to exclude previously described mechanisms of FGFR1 resistance such as AKT overexpression, KRAS mutation, PTEN abnormalities, FGFR1 gatekeeper mutations and MET overactivation46,47.